Evidence map›Paper›PMID 31755218›Full record

ArticleMolecular oncology2020

RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.

Hiroko Toda, Naohiko Seki, Sasagu Kurozumi, Yoshiaki Shinden, Yasutaka Yamada, Nijiro Nohata, Shogo Moriya, Tetsuya Idichi, Kosei Maemura, Takaaki Fujii and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Comprehensive analysis ofTranslational andrology and urology · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Hiroko TodaDepartment of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Naohiko SekiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Japan.ORCID 0000-0003-4731-7956
Sasagu KurozumiDepartment of General Surgical Science, Gunma University Graduate School of Medicine, Japan.
Yoshiaki ShindenDepartment of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Yasutaka YamadaDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Japan.ORCID 0000-0002-0070-1590
Nijiro NohataMSD K.K., Tokyo, Japan.ORCID 0000-0002-6816-2984
Shogo MoriyaDepartment of Biochemistry and Genetics, Chiba University Graduate School of Medicine, Japan.
Tetsuya IdichiDepartment of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Kosei MaemuraDepartment of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Takaaki FujiiDepartment of General Surgical Science, Gunma University Graduate School of Medicine, Japan.
Jun HoriguchiDepartment of Breast Surgery, International University of Health and Welfare, Chiba, Japan.
Yuko KijimaDepartment of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Shoji NatsugoeDepartment of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Kagoshima University · JPChiba University · JPGunma University · JPInternational University of Health and Welfare · JPMSD K.K. (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrantly expressed microRNA (miRNA) are known to disrupt intracellular RNA networks in cancer cells. Exploring miRNA-dependent molecular networks is a major challenge in cancer research. In this study, we performed RNA-sequencing of breast cancer (BrCa) clinical specimens to identify tumor-suppressive miRNA in BrCa. In total, 64 miRNA were identified as candidate tumor-suppressive miRNA in BrCa cells. Analysis of our BrCa signature revealed that several miRNA duplexes (guide strand/passenger strand) derived from pre-miRNA were downregulated in BrCa tissues (e.g. miR-99a-5p/-3p, miR-101-5p/-3p, miR-126-5p/-3p, miR-143-5p/-3p, and miR-144-5p/-3p). Among these miRNA, we focused on miR-101-5p, the passenger strand of pre-miR-101, and investigated its tumor-suppressive roles and oncogenic targets in BrCa cells. Low expression of miR-101-5p predicted poor prognosis in patients with BrCa (overall survival rate: P = 0.0316). Ectopic expression of miR-101-5p attenuated aggressive phenotypes, e.g. proliferation, migration, and invasion, in BrCa cells. Finally, we identified seven putative oncogenic genes (i.e. High Mobility Group Box 3, Epithelial splicing regulatory protein 1, GINS complex subunit 1 (GINS1), Tumor Protein D52, Serine/Arginine-Rich Splicing Factor Kinase 1, Vang-like protein 1, and Mago Homolog B) regulated by miR-101-5p in BrCa cells. The expression of these target genes was associated with the molecular pathogenesis of BrCa. Furthermore, we explored the oncogenic roles of GINS1, whose function had not been previously elucidated, in BrCa cells. Aberrant expression of GINS1 mRNA and protein was observed in BrCa clinical specimens, and high GINS1 expression significantly predicted poor prognosis in patients with BrCa (overall survival rate: P = 0.0126). Knockdown of GINS1 inhibited the malignant features of BrCa cells. Thus, identification of tumor-suppressive miRNA and molecular networks controlled by these miRNA in BrCa cells may be an effective strategy for elucidation of the molecular pathogenesis of this disease.

Indexed as

Genes, Tumor SuppressorAdultAgedAged, 80 and overBreast NeoplasmsCarcinogenesisCarrier ProteinsCell CycleCell Line, TumorCell MovementCell ProliferationDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGene SilencingHMGB3 ProteinCarrier ProteinsDNA-Binding ProteinsESRP1 protein, humanGINS1 protein, humanHMGB3 ProteinMAGOH protein, humanMembrane ProteinsMicroRNAsMIRN101 microRNA, humanNeoplasm ProteinsNuclear ProteinsRNA-Binding ProteinsTPD52 protein, humanVANGL1 protein, humanbreast cancerGINS1microRNAmiR-101-5ppathogenesistumor suppressor

Identifiers

PMID31755218
PMCPMC6998431
OpenAlexW2989912200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.